KYTX
KyvernaยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
KYTX Profile
Kyverna Therapeutics, Inc.
A clinical-stage biopharmaceutical company developing solutions for autoimmune diseases
5980 Horton St., STE 550, Emeryville, CA 94608
--
Kyverna Therapeutics, Inc., was incorporated in Delaware in June 2018 under the name BAIT Therapeutics, Inc., and changed its name to Kyverna Therapeutics, Inc., in October 2019. The company is a patient-centric clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases. The company's goal is to bring disease-modifying therapeutic benefits to patients with autoimmune diseases through a patient-centered approach, a broad platform, insights into the treatment of immune diseases, and lessons learned from the successful application of cell therapy in the medical field.
